Program
ABBV-1480
A development code. Also written as “Telisotuzumab adizutecan plus RC148(ABBV-1480)”.
In AbbVie's pipeline, PD-1, VEGF
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 3since Aug 7, 2026 | Aug 7, 2026 | Dec 2029phase 3 · NCT07756645 |
| RemeGen | 11 open or running | phase 2since Sep 30, 2026 | Sep 30, 2026 | Dec 2027phase 2 · NCT07874282 |
- Named in AbbVie’s own pipeline as
ABBV-1480 (RC148)
, phase 3, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2026First study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to AbbVieAbbVie · NCT07756645 · 940 planned · United States, Puerto Rico
- Sep 30, 2026RemeGen's first study: phase 2 study in Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or CytologyNew to RemeGenRemeGen · NCT07874282 · 200 planned · China
Ahead
- Dec 2027Primary completion: phase 2 study in Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or CytologyRemeGen · NCT07874282
- Dec 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07756645
TargetBeta
“PD-1, VEGF”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07874282Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology · China | 2 | Not yet recruiting | RemeGen | Dec 2027 | 200 |
| NCT07756645Carcinoma, Non-Small-Cell Lung · United States, Puerto Rico | 3 | Recruiting | AbbVie | Dec 2029 | 940 |
How it is read
Names in the registry
- “Telisotuzumab adizutecan plus RC148(ABBV-1480)”, 2 entries
- “ABBV-1480”, 1 entry
Codes read as this program: ABBV1480.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.